Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	90757
Country	France

Category	Medicine, Research & Experimental
Manuscript Type	Prospective Study
Article Title	Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study
Manuscript Source	Unsolicited Manuscript
All Author List	Nathalie Talbodec, Pauline Le Roy, Peggy Fournier, Benoit Lesage, Elodie Lepoutre, François Castex, Jean Michel Godchaux, Lionel Vandeville, Benjamin Bismuth, Xavier Lesage, Pauline Bayart, Michael Genin, Christel Rousseaux, Veronique Maquet, Salvatore Modica, Pierre Desreumaux and Caroline Valibouze
Funding Agency and Grant Number
Corresponding Author	Caroline Valibouze, MD, PhD, Doctor, Department of Digestive Surgery and Transplantation, Lille University, Rue Michel Polonovski, Lille 59037, France. caroline_valibouze@hotmail.fr
Key Words	Chitin-glucan; Irritable bowel syndrome; Abdominal pain; Flatulence; Defecatory disorders; Stool consistency; Natural non-pharmacological treatment
Core Tip	Irritable bowel syndrome is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits. Treatment options are limited and often inadequate, which leads to dissatisfaction among patients receiving standard medical care. Our study showed that 4 weeks of daily treatment with GASTRAP® DIRECT, a class IIa medical formulation containing a combination of chitin-glucan and simethicone, is well tolerated and rapidly effective in reducing abdominal pain, bloating, abdominal distension, and flatulence with an improvement of stool consistency and defecatory disorders.
Citation	Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; In press

Received	2024-01-25 21:32
Peer-Review Started	2024-01-25 21:32
To Make the First Decision
Return for Revision	2024-02-28 20:45
Revised	2024-03-19 22:11
Second Decision	2024-05-08 02:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-05-08 05:58
Articles in Press	2024-05-08 05:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com